Cemat A/S
Nasdaq Copenhagen
Nikolaj Plads 6
DK-1067 Copenhagen K
Copenhagen, 22 March 2021
ANNOUNCEMENT no 8/2021
Closely related persons transactions
Pursuant to Article 19 of the market abuse regulation Cemat A/S hereby announces the following information received 22 March 2021.
| Name: | Peter Taero Nielsen |
| Reason for filing: | Closely related person to Joanna Lucyna Iwanowska-Nielsen, member of the board of directors in the company |
| Company name: | Cemat A/S |
| Identification code and name: | ISIN DK0010271584 |
| Transaction type: | Purchase |
| Date: | 18 March 2021 |
| Market: | Nasdaq Copenhagen |
| Number of traded shares: | 45,764 |
| Price: | 0.48 |
Cemat A/S
Jaroslaw Pawel Lipinski
CEO
This announcement has been prepared in a Danish-language and an English-language
version. In case of doubt, the Danish version prevails.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
NTR Holding A/S9.1.2026 09:37:54 CET | Press release
Nasdaq Copenhagen A/S godkender afnotering af NTR Holding A/S’ B-aktier
Alveus Therapeutics Inc9.1.2026 09:13:19 CET | Pressemeddelelse
Alveus Therapeutics annoncerer serie A-financiering på 160 mio. USD til næste generations behandlinger mod fedme og stofskiftesygdomme
Yacht Club de Monaco9.1.2026 09:05:00 CET | Press release
At the Yacht Club de Monaco a year of transition and innovation begins
Onco3R Therapeutics BV9.1.2026 09:00:00 CET | Press release
O3R-5671 Pharmacokinetic and Pharmacodynamic Data to be Presented at ECCO and Dosing in Final Cohort in First-in-human study initiated
Zealand Pharma9.1.2026 08:00:00 CET | Press release
Zealand Pharma enters agreement with DCAI to use Gefion AI supercomputer to accelerate drug discovery and support Metabolic Frontier 2030 strategy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
